Identifying risk of cancer before it strikes

OCB has developed a simple mouth swab test which identifies whether individuals are at increased risk of developing colorectal cancer.

Early lifestyle changes, such as exercise, healthy diet and committing to regular screenings, could make their future very different.

ColoPredict is a complementary test to existing colorectal cancer screening programmes, offering a cost-effective addition that addresses the risk profile of individuals which has been .clinically validated in 47,000 individuals.

Product Pipeline

Beyond colorectal cancer

Our high performance biomarker tests were developed to aid clinical decision-making and improve patient outcomes in colorectal cancer. The technology, however, is appropriate for use in other areas of oncology and our team is developing the tests in other cancers.

Research is ongoing into use of biomarker technologies in breast cancer and prostate cancer, where 5FU/capecitabine are likely to remain mainstays of chemotherapy regimens.

References

Palles C, Cazier JB, Howarth KM, Domingo E, Jones AM, Broderick P, Kemp Z, Spain SL, Almeida EG, Salguero I, Sherborne A, Chubb D, Carvajal-Carmona LG, Ma Y, Kaur K, Dobbins S, Barclay E, Gorman M, Martin L, Kovac MB, Humphray S, The CORGI Consortium, Thomas HJ, Maher E, Evans G, Lucassen A, Cummings C, Stevens M, Walker L, Halliday D, Armstrong R, Paterson J, Hodgson S, Homfray T, Side L, Izatt L, Donaldson A, Tomkins S, Morrison P, Goodman S, Brewer C, Henderson A, Davidson R, Murday V, Cook J, Haites N, Bishop T, Sheridan E, Green A, Marks C, Carpenter S, Broughton M, Greenhalge L, Suri M, The WGS500 Consortium, Steering Committee:, Donnelly P, Bell J, Bentley D, McVean G, Ratcliffe P, Taylor J, Wilkie A, Operations Committee:, Donnelly P, Broxholme J, Buck D, Cazier JB, Cornall R, Gregory L, Knight J, Lunter G, McVean G, Taylor J, Tomlinson I, Wilkie A, Sequencing & Experimental Follow-up:, Buck D, Gregory L, Humphray S, Kingsbury Z, Dat.a Analysis:, McVean G, Donnelly P, Cazier JB, Broxholme J, Grocock R, Hatton E, Holmes CC, Hughes L, Humburg P, Kanapin A, Lunter G, Murray L, Rimmer A, Lucassen A, Holmes CC, Bentley D, Donnelly P, Taylor J, Petridis C, Roylance R, Sawyer EJ, Kerr DJ, Clark S, Grimes J, Kearsey SE, Thomas HJ, McVean G, Houlston RS, Tomlinson I. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet 45(2):136-144. 2012.
Kinnersley B, Migliorini G, Broderick P, Whiffin N, Dobbins SE, Casey G, Hopper J, Sieber O, Lipton L, Kerr DJ, Dunlop MG, Tomlinson IP, Houlston RS The TERT variant rs2736100 is associated with colorectal cancer risk. British Journal of Cancer 107(6):1001-1008. 2012.
La Thangue, NB and Kerr DJ. Predictive biomarkers: a shift towards personalised cancer medicine. Nature Reviews Clinical Oncology 8, 587-596. 2011.
Houlston RS, Cheadle J, Dobbins SE, Tenesa A, Jones AM, Howarth K, Spain SL, Broderick P, Domingo E, Farrington S, Prendergast JG, Pittman AM, Theodoratou E, Smith CG, Olver B, Walther A, Barnetson RA, Churchman M, Jaeger EE, Penegar S, Barclay E, Martin L, Gorman M, Mager R, Johnstone E, Midgley R, Niittymäki I, Tuupanen S, Colley J, Idziaszczyk S; COGENT Consortium, Thomas HJ, Lucassen AM, Evans DG, Maher ER; CORGI Consortium; COIN Collaborative Group; COINB Collaborative Group, Maughan T, Dimas A, Dermitzakis E, Cazier JB, Aaltonen LA, Pharoah P, Kerr DJ, Carvajal-Carmona LG, Campbell H, Dunlop MG, Tomlinson IP. Meta-analysis of three UK genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. Nature Genetics, 42,973-77. 2010.
Luis S, Spain S, Tomlinson I, Kerr D; Houlston R, Cazier J. Common variation at the Adiponectin locus is not associated with colorectal cancer risk in the United Kingdom. Human Molecular Genetics, 18, 1889-1892. 2008.
Cogent Study Group Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nat Genetics 40, 1426-35, 2008.
Tomlinson I, Webb E, Carvajal-Carmona L, Broderick P, Howarth K, Pittman A, Spain S , Lubbe S, Walther A, Sullivan K, Jaeger E, Fielding S, Rowan A, Vijayakrishnan J, Domingo E, Chandler I, Kemp Z, Qureshi M, Farrington S, Tenesa A, Prendergast J, Barnetson R, Penegar S, Barclay E, Wood W, Martin L, Gorman M, Thomas H, Peto J, Bishop T, Gray R, Maher E, Lucassen A, Kerr D, Evans E, The CORGI Consortium, Schafmayer C, Buch S, Izke H, Hampe J, Schreiber S, John U, Koessler T, Pharoah P, van Wezel T, Morreau H, Wijnen J, Hopper J, Southey M, Giles G, Severi G, Castellvı´-Bel S, Ruiz-Ponte C, Carracedo A, Castells A, The EPICOLON Consortium, Fo¨rsti A, Hemminki K, Vodicka P, Naccarati A, Lipton L, WC Ho J, Cheng K, Sham P, Luk J, Agu´ ndez J , Ladero J, de la Hoya M, Calde´s T, Niittyma¨ki I, Tuupanene S, Karhu A, Aaltonen L, CazierJB, Campbell H, Dunlop M, & Houlston R. A genome-wide association study identifies novel colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nature Genetics. 40, 623-630. 2008.
Jaeger E, Webb E, Howart K, Carvajal-Carmona L, Rowan A, Broderick P, Walther A, Spain S, Pittma A, Kemp Z, Sullivan K, Heinimann K, Lubbe, Domingo E, Barclay E, Martin L, Gorman M, Chandler I, Vijayakrishna J, Wood, Papaemmanuil E, Penegar S, Qureshi M, members of the CORGI consortium, Tenesa A, Cazier JB, Kerr D, Gray R, Peto P, Dunlop M, Thomas HH, Houlston R, Tomlinson I. Common genetic variants at the CRAC1 (HMPS) locus on chromosome 15q13.3 influence colorectal cancer risk. Nature Genetics, 40: 26-28, 2007.
Broderick P, Carvajal-Carmona L, Pittman AM, Webb E, Howarth K, Rowan A, Lubbe S, Spain S, Sullivan K, Fielding S, Jaeger E, Vijayakrishnan J, Kemp Z, Gorman M, Chandler I, Papaemmanuil E, Penegar S, Wood W, Sellick G, Qureshi M, Teixeira A, Domingo E, Barclay E, Martin L, Sieber O, Kerr D, Gray R, Peto J, Cazier JP, Tomlinson I, Houlston R. A genome-wide association study shows that common alleles of : SMAD7: influence colorectal cancer risk. Nature Genetics 39, 1315 – 1317 (14 Oct 2007).
Tomlinson I, Webb E, Carvajal-Carmona L, Broderick P, Kemp Z, Spain S, Penegar S, Chandler I, Gorman M, Wood W, Barclay E, Lubbe S, Martin L, Sellick G, Jaeger E, Hubner R, Wild R, Rowan A, Fielding S, Howarth K, Silver A, Atkin W, Muir K, Logan R, Kerr D, Johnstone E, Sieber O, Gray R, Thomas H, Peto J, Cazier JB, Houlston R. A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nature Genetics 39, 984-988. 2007

News & Press

Oxford Cancer Biomarkers announces first patient into its clinical study for its precision oncology OncoProg test for colorectal cancer

January 14, 2025

PRESS RELEASE: Oxford Cancer Biomarkers closes funding round led by Plutus Investment Group LLP

April 3, 2023

PRESS RELEASE: OncoHelix and Oxford Cancer Biomarkers Enter into a Partnership to Offer Breakthrough Cancer Genetic Screening Test to Canadians

March 20, 2023

PRESS RELEASE: Oxford Cancer Biomarkers granted Artificial Intelligence in Health and Care Award

March 3, 2023

PRESS RELEASE: Oxford Cancer Biomarkers announces European expansion of life-saving chemotherapy toxicity test and independent, real-world evidence of patient benefit

September 26, 2022

PRESS RELEASE: Oxford Cancer Biomarkers appoints Joanna Smart as Chair of the Board

January 6, 2022

Health Economics model for OncoProg® commissioned

July 30, 2021

PRESS RELEASE: OncoProg receives CE mark

July 19, 2021

PRESS RELEASE: Kyoung Mee Lee joins our Board of Directors

April 30, 2021

Our Other Products

Reduces risk of chemotherapy toxicity

Identifies whether your patient is at risk of capecitabine toxicity. Enables a clinically rotreatment decisions and reduces the risk of severe adverse effects with ToxNav.

Improve your patients’ quality of life and reduce treatment costs. Proven to be clinically effective.

Find Out More

Guide chemotherapy usage using AI analysis of large clinical datasets

What if you could find out which of your patients are at low, intermediate or high risk of colorectal cancer relapse?

OncoProg uses innovative digital pathology and proprietary algorithms to create a risk profile for your patients and help inform your next clinical decision.

Find Out More